Lyra Therapeutics, Inc. (LYRA) Financials

LYRA Assets vs Liabilities

DateAssetsLiabilities
Sept. 30, 2025 43.7 million 48.0 million
June 30, 2025 52.6 million 51.0 million
March 31, 2025 56.3 million 52.4 million
Dec. 31, 2024 66.3 million 54.8 million

LYRA Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2025 -7.4 million 34000
June 30, 2025 -6.6 million 914000
March 31, 2025 -8.8 million 825000
Dec. 31, 2024 -11.3 million 1.9 million

LYRA Net Income

No data available :(

LYRA Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2025 22.1 million 26.7 million 31.4 million
June 30, 2025 29.8 million 27.9 million 32.5 million
March 31, 2025 31.7 million 29.1 million 33.4 million
Dec. 31, 2024 40.6 million 30.3 million 34.4 million

LYRA Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2025 1.8 million
June 30, 2025 1.3 million
March 31, 2025 65.8 million
Dec. 31, 2024 65.1 million

LYRA Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2025 - 4.0 million 2.1 million -
June 30, 2025 20000 5.1 million 3.5 million -
March 31, 2025 - 4.9 million 3.3 million -
Dec. 31, 2024 58000 6.4 million 3.6 million -

LYRA Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2025 25000 100000
June 30, 2025 183000 200000
March 31, 2025 183000 -
Dec. 31, 2024 209000 -

LYRA

Price: $0.73

52 week price:
0.31
37.50

Earnings Per Share: -22.90 USD

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 10913

Market Capitalization: 878566

Links: